Research advances in the role of DPP4 inhibitor in the pathogenesis of nonalcoholic fatty liver disease

Abstract:

Nonalcoholic fatter liver disease（NAFLD） refers to liver lesions induced by the factors other than alcohol，drugs，and hereditary diseases，and its pathogenesis may be insulin resistance，dyslipidemia，and oxidative stress. Hypoglycemic agents including DPP4 inhibitor exert a protective effect against NAFLD，possibly by improving insulin resistance and inhibiting lipid synthesis and in－flammatory response. The incidence rate of NAFLD is increasing year by year，but there are still no effective intervention measures in clinical practice. Treatment measures should be actively explored based on pathogenesis.